The Effectiveness of Idazoxan in Treating TRD
Sponsor
Sheba Medical Center (Other)
Overall Status
Withdrawn
CT.gov ID
NCT00294944
Collaborator
(none)
1
Study Details
Study Description
Brief Summary
Assessing the effectiveness of Idazoxan as a treatment for depressive patients who did not respond to treatment with SSRI
| Condition or Disease | Intervention/Treatment | Phase |
|---|---|---|
| Phase 3 |
Study Design
Study Type:
Interventional
Allocation:
Randomized
Intervention Model:
Parallel Assignment
Masking:
Double
Outcome Measures
Primary Outcome Measures
Eligibility Criteria
Criteria
Ages Eligible for Study:
18 Years
to 65 Years
Sexes Eligible for Study:
All
Inclusion Criteria:
-
MDD patients
-
Did not respond to at least one treatment of 4-6 weeks of SSRI in adequate dose
-
In or out patients
Exclusion Criteria:
- Psychotic symptoms
Contacts and Locations
Locations
| Site | City | State | Country | Postal Code | |
|---|---|---|---|---|---|
| 1 | Chaim Sheba Medical Center | Ramat-Gan | Israel | 52621 |
Sponsors and Collaborators
- Sheba Medical Center
Investigators
- Principal Investigator: Joseph Zohar, MD, Sheba Medical Center
Study Documents (Full-Text)
None provided.More Information
Publications
None provided.Responsible Party:
,
,
ClinicalTrials.gov Identifier:
NCT00294944
Other Study ID Numbers:
- SHEBA-05-3911-JZ-CTIL
First Posted:
Feb 22, 2006
Last Update Posted:
Jan 29, 2008
Last Verified:
Jan 1, 2008